Anavex Reports Results of ANAVEX 2-73 (blarcamesine) in P-III (AVATAR) Trial for the Treatment of Rett Syndrome
- The P-III (AVATAR) trial evaluates the safety, tolerability, PK, and efficacy of ANAVEX 2-73 (30mg) vs PBO in 36 female patients with Rett syndrome for 7wks.
- The trial met 1EPs & 2EPs i.e., improvement of RSBQ AUC (72.2% vs 38.5%); emotional behavior symptoms (ADAMS) (52.9% vs 8.3%); c CGI-I response (72.2% vs 38.5%), reductions in Rett syndrome symptoms with changes in biomarkers (GABA & L-AAA), was well tolerated. The results were consistent with the known safety profile of ANAVEX 2-73
- ANAVEX 2-73 has received FTD, RPDD & ODD from the US FDA for Rett syndrome. The therapy is being evaluated in the P-II/III (EXCELLENCE) study for the same indication in patients aged 5 to 17yrs.
Ref: Globe Newswire | Image: Anavex
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at firstname.lastname@example.org